{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-029169","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2023-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.963119+00:00","generated_at":"2026-06-11T08:35:50.225087+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vivos Q2 revenue falls to $3.4M (-19% YoY); net loss narrows 21% but now expects added financing","bullets":["Revenue $3.4M, down 19% YoY from $4.2M; gross profit $2.1M (62% margin).","Net loss reduced by $1.5M (21% YoY) reflecting cost cuts.","Operating expenses cut 31% YoY ($2.9M reduction).","Cash $3.9M; now expects to need additional financing as sales growth stalled.","Patients treated ~40,000 (up from ~28,000); DSO pilots and first DME distribution deal signed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-029169","json":"https://secwatch.observer/filing/0001493152-23-029169.json","markdown":"https://secwatch.observer/filing/0001493152-23-029169.md","text":"https://secwatch.observer/filing/0001493152-23-029169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223029169/0001493152-23-029169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223029169/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T08:35:50.225087+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e8f6393bc8d5f13f2b9a2e8569d9a689b7dc5e7e","claim":"Vivos Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $3.4 million.","evidence_excerpt":"reported financial results and operating highlights for the second quarter and six months ended June 30, 2023. Second Quarter 2023 Financial and Operating Summary ● Revenue was $3.4 million for the second quarter of 2023 and $7.3 million for the six months ended June 30, 2023, compared to $4.2 million and $7.8 million for the three and six months ended June 30,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223029169/0001493152-23-029169-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$3.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}